Skip to main
LFMD

LifeMD (LFMD) Stock Forecast & Price Target

LifeMD (LFMD) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LifeMD is positioned for long-term success due to their comprehensive platform and expansion into high-demand areas like Women's Health and Dermatology. With their use of AI technology and strong financial standing, they are well-equipped to continue their growth and meet increasing demand. Their unique approach and alignment with popular brands also sets them apart from competitors and mitigates regulatory risk.

Bears say

LifeMD is a direct-to-patient healthcare company in a highly competitive and regulated market, and its strategies may not work as intended. The company's current valuation of EV / 9.9x 2027E EBITDA is high compared to its projected revenue growth and potential risks such as cybersecurity threats, product recalls, and dependence on third-party suppliers. The potential for dilution due to the company's young and growing nature and uncertainty surrounding COVID-19 may also hinder the achievement of the 12-month price target of $10 based on a comparable universe analysis.

LifeMD (LFMD) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LifeMD (LFMD) Forecast

Analysts have given LifeMD (LFMD) a Strong Buy based on their latest research and market trends.

According to 7 analysts, LifeMD (LFMD) has a Strong Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LifeMD (LFMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.